Host: The Japanese Pharmacological Society
Name : The 97th Annual Meeting of the Japanese Pharmacological Society
Number : 97
Location : [in Japanese]
Date : December 14, 2023 - December 16, 2023
Against the backdrop of inappropriate use of antimicrobials, the number of antimicrobial-resistant (AMR) bacteria is increasing worldwide. On the other hand, the development of new antimicrobials with efficacy to counter them is on the decline, making this a major issue internationally. Infections caused by AMR bacteria are considered to be “silent pandemic” as this is spreading steadily and global threat.
In the “Global Action Plan on Antimicrobial Resistance” by the World Health Organization (WHO), donor countries are required to support the achievement of the Global Action Plan. In particular, it is considered important to ensure the availability of antimicrobials with measures to maintain their effectiveness, and to work on new prevention, diagnosis, and treatment methods. In Japan, “National Action Plan on AMR (2023-2027)” was released in April 2023. It emphasizes the importance of collaborating with various fields from an international perspective to promote countermeasures against drug resistance.
In this presentation, I will show the characteristics and global development strategy of novel siderophore cephalosporin, cefiderocol, which has activity against Gram-negative bacteria, including multidrug-resistant bacteria. In addition, I will introduce GARDP-led efforts toward the clinical use of flomoxef, which has activity against ESBL-producing bacteria, for sepsis in neonates. I hope that this will be an opportunity to think about the importance of fusion of various fields and international cooperation to combat AMR.
